Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galderma Granted Manufacturing License Updates for New Biologics Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Galderma Granted Manufacturing License Updates for New Biologics Capabilities

Establishes the Uppsala site as a world-class center of excellence for dermatology products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galderma recently announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its growth and innovation roadmap.

The license updates issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline assets in Injectable Aesthetics, RelabotulinumtoxinA is a next-generation liquid neuromodulator in Injectable Aesthetics developed using Galderma’s proprietary PEARL technology. This technology preserves the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A.

“Our commitment to leading innovation in dermatology is reflected in our high-performance operations,” said Adrian Murphy, head of global operations, Galderma. “These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics